CC
ABUS icon

Centiva Capital’s Arbutus Biopharma ABUS Stock Holding History

Centiva Capital’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-30,724
Closed -$100K – 1494
2024
Q4 		$100K Sell
30,724
-9,276
-23% -$34.1K ﹤0.01% 1493
2024
Q3 		$154K Sell
40,000
-12,800
-24% -$49.1K ﹤0.01% 1895
2024
Q2 		$163K Sell
52,800
-1,300,080
-96% -$3.9M ﹤0.01% 1749
2024
Q1 		$3.49M Sell
1,352,880
-67,840
-5% -$176K 0.09% 174
2023
Q4 		$3.55M Buy
1,420,720
+349,015
+33% +$684K 0.08% 225
2023
Q3 		$2.18M Buy
+1,071,705
New +$2.25M 0.05% 356
2022
Q2 		– Sell
-300,000
Closed -$894K – 1643
2022
Q1 		$894K Buy
300,000
+270,500
+917% +$828K 0.02% 753
2021
Q4 		$115K Sell
29,500
-28,000
-49% -$109K ﹤0.01% 1043
2021
Q3 		$247K Buy
+57,500
New +$192K 0.02% 844

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
FC
Foursixthree Capital New York $268M AUM 115.24% 1-Year Est. Return
BCP
BlackBarn Capital Partners New York $1.24B AUM 55.98% 1-Year Est. Return

Centiva Capital's ABUS Position: Q1 2025 in Review

Centiva Capital sold out of Arbutus Biopharma (ABUS) in Q1 2025, closing a stake of 30,724 shares — an estimated $100K sold.

Centiva Capital first reported a position in ABUS in Q3 2021 and held it in 9 quarters. The position peaked at $3.55M in Q4 2023. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2025.

  • Centiva Capital reported no remaining Arbutus Biopharma position as of Q1 2025 after selling out during the quarter.
  • Centiva Capital sold 30,724 Arbutus Biopharma shares in Q1 2025, an estimated $100K.
  • Centiva Capital first reported a position in Arbutus Biopharma in Q3 2021 and held it in 9 quarters.
  • Centiva Capital's Arbutus Biopharma position peaked at $3.55M in Q4 2023.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2025.

Based on Centiva Capital's 13F filing for Q1 2025, filed 15 May 2025.